Eli Lilly and Company $LLY Position Lessened by South Dakota Investment Council

South Dakota Investment Council cut its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 6.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,737 shares of the company’s stock after selling 2,560 shares during the period. Eli Lilly and Company accounts for 0.8% of South Dakota Investment Council’s holdings, making the stock its 20th biggest position. South Dakota Investment Council’s holdings in Eli Lilly and Company were worth $44,822,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. M. Kulyk & Associates LLC grew its position in Eli Lilly and Company by 4.3% during the third quarter. M. Kulyk & Associates LLC now owns 8,286 shares of the company’s stock valued at $9,588,000 after buying an additional 341 shares during the period. Legacy Financial Group LLC increased its holdings in Eli Lilly and Company by 37.4% in the third quarter. Legacy Financial Group LLC now owns 261 shares of the company’s stock valued at $302,000 after buying an additional 71 shares in the last quarter. Rollins Financial Advisors LLC raised its position in shares of Eli Lilly and Company by 0.6% in the third quarter. Rollins Financial Advisors LLC now owns 3,124 shares of the company’s stock worth $3,615,000 after acquiring an additional 19 shares during the period. Bridges Investment Management Inc. raised its position in shares of Eli Lilly and Company by 38.5% in the third quarter. Bridges Investment Management Inc. now owns 35,294 shares of the company’s stock worth $40,838,000 after acquiring an additional 9,815 shares during the period. Finally, Ironwood Investment Counsel LLC boosted its stake in shares of Eli Lilly and Company by 2.1% during the 3rd quarter. Ironwood Investment Counsel LLC now owns 3,647 shares of the company’s stock worth $4,220,000 after acquiring an additional 74 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.

Key Stories Impacting Eli Lilly and Company

These are some of the LLY stories that stood out recently:

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,412.63 on Wednesday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm has a fifty day moving average of $1,253.71 and a 200 day moving average of $1,114.28. The firm has a market cap of $1.33 trillion, a PE ratio of 45.85, a PEG ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,475.25.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company’s revenue was up 38.6% compared to the same quarter last year. During the same period last year, the firm posted $7.02 earnings per share. As a group, research analysts predict that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 22.46%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a research report on Monday, November 2nd. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Jefferies Financial Group upped their price target on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a report on Monday, November 9th. Berenberg Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a research report on Tuesday, September 15th. Finally, JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,422.00.

View Our Latest Report on Eli Lilly and Company

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.